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1. Introduction
Pharmacokinetics is the study of the time course of a drug and its metabo-
lites after introduction into the body. Pharmacokinetic studies are carried
out extensively in drug development as they provide an invaluable aid in
describing a drug’s absorption, distribution and elimination characteristics.
In this paper we consider an alternative to the traditional compartment
models used for pharmacokinetic data, based on a generalized linear model.
Wakeﬁeld (2004) brieﬂy considered such models for a single individual; here
we provide more details and extend the approach to multiple individuals.
The structure of this paper is as follows. In Section 2 we review compart-
mental models and inference for such models. Sections 3 and 4 describe the
log-linear gamma generalized linear models (GLMs) for single and multiple
individuals, respectively. The use of these models is demonstrated in Section
5 and a concluding discussion is provided in Section 6.
2. Compartmental Models
Traditionally, to carry out statistical analysis of pharmacokinetic data the
body is modeled as a system of compartments within which drug kinetics
are assumed to be homogeneous, leading to concentration-time proﬁles that
are sums of exponential. Gibaldi and Perrier (1982) provide a comprehensive
account of pharmacokinetic models and principles, and Godfrey (1983) an ac-
count of compartmental modeling in general. Pharmacokinetic modeling via
a compartmental system is a convenient visualization but the compartments
often have no physiological meaning. Given the simplicity of such systems,
the belief in the speciﬁc model chosen is often questioned, but certain phys-
iological parameters are important for clinical application. For example the
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clearance, which is deﬁned as the volume of blood that is cleared of drug in
unit time, is of fundamental interest, as are the elimination half-life, that is
the time taken for the drug concentration to drop by 50%, and, for oral doses,
the maximum concentration and the time to maximum concentration. The
classic text due to Rowland and Tozer (1995) takes a “model-free” approach
to pharmacokinetics in that the emphasis is on the physiological parame-
ters, rather than on compartmental systems. Other authors (Weiss (1986),
Weiss (1987)) have also strayed from compartmental models, and instead
concentrated upon the estimation of model-free quantities of interest via a
convenient representation.
For an intravenous bolus dose of size D, a p compartment model with
ﬁrst-order kinetics leads to the time course of the concentration
µ(t) =
D
V
p∑
k=1
Ak exp (βkt) , (1)
a sum of exponentials. The parameter V is an “apparent” volume that
converts total amounts of drug to concentrations; it is an apparent volume
since it may exceed the total volume of blood in the body due to binding,
etc. The Ak parameters describe the relative contributions of each of the p
exponentials. The stochastic part of the model includes measurement error
and errors due to model misspeciﬁcation. Let y(tij) be the jth measured
concentration for the ith individual at time tij . Assay precision is often
found to increase with increasing true concentrations and models of the form
y(tij) = µ(tij) + δ(tij)
where δ(tij) ∼ind N {0, µ(tij)
γσ2δ} with γ > 0 have been used (e.g. Davidian
and Giltinan (1995)). An alternative, with constant coeﬃcient of variation,
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is
log y(tij) = log µ(tij) + (tij)
with (tij) ∼iid N(0, σ
2). Lindsey et al. (2000) have suggested combining a
compartmental model mean with a gamma error model.
We consider in detail the one-compartment model with ﬁrst-order absorp-
tion and elimination. Let wk(t) represent the amount of drug in compartment
k, k = 0, 1 at time t, with compartment 0 representing the site from which
absorption occurs; compartment 1 may be nominally thought of as corre-
sponding to blood. The drug ﬂow between the compartments is described
by the diﬀerential equations
dw0
dt
= −kaw0,
dw1
dt
= kaw0 − kew1,
where ka is the absorption rate constant associated with the ﬂow from com-
partment 0 to compartment 1, and ke is the elimination rate constant. At
time zero the initial dose is w0(0) = D, and given V , the volume of distribu-
tion, we have
µ(t) =
Dka
V (ka − ke)
{exp(−ket)− exp(kat)} . (2)
A common error model is:
log yij = logµij + ij
with ij ∼iid N(0, σ
2), where yij = y(tij) and µij = µ(tij). Model (2) is some-
times known as the “ﬂip-ﬂop” model because there is non-identiﬁability; the
parameters (V, ka, ke) give the same curve as the parameters (V ke/ka, ke, ka).
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To enforce identiﬁability it is typical to assume that ka > ke > 0. This
identiﬁability issue become worse as the number of compartments increases.
The derived parameters of interest, given in terms of (V, ka, ke), are:
• the time to maximum concentration:
tmax =
1
ka − ke
log
(
ka
ke
)
;
• the maximum concentration:
cmax = µ(tmax) =
D
V
(
ke
ka
)ke/(ka−ke)
;
• the clearance (initial dose divided by the area under the concentration
curve):
Cl = V × ke;
• the elimination half-life:
t1/2 =
log 2
ke
.
The ﬁrst three quantities may be viewed as model-free in the sense that for
any assumed functional concentration-time form they may be calculated. The
half-life depends on the dominant term for large times being an exponential
with positive ke.
Model (2) is a nonlinear regression model and inference may proceed
from either a frequentist or Bayesian perspective; Bates and Watts (1988)
discuss in detail the intrinsic non-linearity of compartment models, which
can lead to diﬃculties in both computation and asymptotic inference. For
a Bayesian approach (which may be essential if only sparse data is available
on a particular individual, Wakeﬁeld (1996)) we advocate prior speciﬁcation
6
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in terms of the derived parameters of interest. Such priors are easier to
specify, though one disadvantage is that the transformation from priors on
derived parameters to model parameters may require numerical root-solving
which complicates computation. For example, this problem arises for the
transformation (cmax, tmax, t1/2) → (V, ka, ke).
3. Gamma Generalized Linear Models for Single Individuals
3.1 Model Description
We can rewrite the one-compartment model (2) as
µ(t) = D exp(β0 + β1t) [1− exp{−(ka − ke)t}]
where β0 = log{ka/[V (ka− ke)]} and β1 = −ke. This suggests an alternative
to the compartment model, using a GLM and ﬁtting the log-linear fractional
polynomial model:
E(yij) = µij = Di exp (β0 + β1tij + β2/tij) . (3)
Here, β2 determines the absorption, and we require β1 < 0 and β2 < 0 to
ensure an increasing absorption phase and a decreasing elimination phase.
The data are assumed to be gamma distributed, with yij ∼ Ga{φ
−1, (µijφ)
−1}
so that φ1/2 is the coeﬃcient of variation.
Again, we are interested in the derived parameters, expressed in terms of
(β0, β1, β2):
• the time to maximum concentration:
tmax =
(
β2
β1
)
1/2
;
• the maximum concentration:
cmax = D exp[β0 − 2{β1β2)
1/2};
7
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• the clearance:
Cl =
(β1/β2)
1/2
2 exp(β0)K1[2(β1β2)1/2]
; (4)
where Kn[x] denotes a modiﬁed Bessel function of the second kind of
order n.
• the elimination half-life:
t1/2 = −
log 2
β1
.
3.2 Likelihood Inference
Since the form of (3) is a generalized linear model, estimation is straight-
forward using maximum likelihood for the ﬁxed parameters, and a moment
estimator for the dispersion parameter.
Conﬁdence intervals for the derived parameters of interest may be based
on the asymptotic distribution of the MLE using the delta method on the
log of the parameters; the variances of these are provided in the appendix.
3.3 Bayesian Inference
We would rather place priors on the derived parameters of interest since
pharmacokineticists ﬁnd these more straightforward to think about and may
combine information from a variety of sources, and not just on previous
compartmental analyses. Model comparisons of mean models and error dis-
tributions via Bayes factors are also more interpretable since the same priors
may be used across models.
The posterior distribution is not tractable and so we resort to simulation-
based methods. A convenient way to implement the Bayesian approach for
low-dimensional posteriors with informative priors is via a rejection algo-
rithm which takes as generating density the prior distribution (Wakeﬁeld
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(1994)). This approach produces independent samples from the posterior
and so can be automated since it does not require subjective assessment of
burn-in or convergence. Unlike Markov chain Monte Carlo (MCMC) it also
allows straightforward calculation of Bayes factors for model comparison.
Let θ denoted the parameters, for example, the collection (t1/2, tmax, cmax,
cv), with prior distribution π(θ), and let M = supθ p(y|θ) be the maximized
likelihood. Then the rejection algorithm proceeds as follows:
1. Generate U ∼ U(0, 1) and θ ∼ π(θ), independently.
2. Accept θ if
U <
p(y|θ)
M
,
otherwise reject θ.
3. Return to 1.
This approach requires the prior to be proper; proper priors are in general
needed for compartmental models in order to ensure a proper posterior dis-
tribution. The acceptance probability of the algorithm is pa = p(y)/M , so
an estimate of the prior predictive is
p˜(y) = Mp̂a (5)
To compare models M0 and M1, the Bayes factor is
p(y|M0)
p(y|M1)
,
the ratio of the marginal distributions of the data under the two models. An
estimate of the marginal distribution can be obtained for each model using
9
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the observed acceptance rate via (5). Alternatively, an importance sampling
algorithm can be used; see Pauler, Wakeﬁeld and Kass (1999) for details.
Implementation via the rejection algorithm is straightforward for the
GLM, but for the compartment model requires root-solving to ﬁnd ka, in-
creasing the computational burden. The samples may be transformed for
other quantities of interest, for example, the clearance can be calculated
directly via substitution of β samples into (4)
4. Gamma Generalized Linear Models for Multiple Individuals
4.1 Model Description
For multiple individuals we may use a generalized linear mixed model
(GLMM):
yij ∼ Ga{φ
−1, (µijφ)
−1} (6)
µij = Di exp (βi0 + βi1tij + βi2/tij) (7)
βi ∼ N(β,Σ) (8)
where βi = (βi0, βi1, βi2)
T and Σ is a 3× 3 covariance matrix.
Here we have speciﬁed random eﬀects for each element of β. However,
we require βi0 > 0, βi1 < 0, βi2 < 0 for the ﬁtted curve to be meaningful;
one possibility is to re-parameterize and specify normal random eﬀects for
{βi0, log(−βi1), log(−βi2)}.
4.2 Likelihood Inference
Model (8) is a straightforward GLMM and so can ﬁtted using standard
software, for example, the lmer() function in R. Unfortunately, if we need
to re-parameterize the model it is no longer a GLM, and we need to use a
more general random eﬀects ﬁtting procedure (such as nlme() in R). Thus
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http://biostats.bepress.com/uwbiostat/paper309
we lose one of the beneﬁts of this formulation over the compartment model.
4.3 Bayesian Inference
In the Bayesian framework the illegal values in the parameter space can be
avoided using the prior, though the normality assumption of random eﬀects
may be more reasonable on a transformed scale. It is perhaps more natural
to specify the random eﬀects on the parameters of interest and so we combine
(6) and (7) with the alternative random eﬀects model:
log θi ∼ N(µ,Σ) (9)
where θi = f(βi) = (ti1/2, timax, cimax)
T transforms the likelihood parameter-
ization βi to the prior parameterization θi. The model is completed with
priors for φ, µ and Σ.
The rejection algorithm described for the ﬁxed eﬀects model is no longer
feasible for this model, as the acceptance probabilities are too small. How-
ever, samples may be generated using an MCMC algorithm. For example,
it is straightforward to express this model in WinBUGS (Spiegalhalter et al.
(2003)).
5. Application
We illustrate the models using data on 12 subjects given an oral dose of
the anti-asthmatic agent theophylline, with 10 concentration measurements
obtained from each individual over the subsequent 25 hours. The data are
shown in Figure 1; they were originally analyzed in Upton et al. (1982) and
are available from the Resource Facility for Population Kinetics at
http://www.rfpk.washington.edu.
[Figure 1 about here.]
11
Hosted by The Berkeley Electronic Press
5.1 Individual Fitting
To compare the compartment and GLM models, we ﬁt the single models
to each of the twelve individuals. The ﬁtted curves in Figure 1, corresponding
to the MLEs for the compartmental and generalized linear models, are very
similar. The computation time for the frequentist models was slightly greater
for the GLM, though the ﬁtting for all 12 individuals was negligible (less than
a third of a second for both model classes). For the Bayesian models we used
independent log-normal priors for t1/2, tmax, cmax, cv, with medians 8, 1.5,
9, 0.1 respectively and 90th percentiles 26, 6, 36, 10. We calculated Bayes
factors, as a side-product of the rejection method; using the guidelines given
in Kass and Raftery (1995) six individuals have positive evidence in favor
of the GLM, and two have positive evidence in favor of the compartmental
model, so that neither model is consistently preferred. Marginal inference for
the derived parameters of interest was consistent across models; for example,
Figure 2 shows similar histogram posterior representations for t1/2, tmax and
clearance for the ﬁrst individual.
[Figure 2 about here.]
Plots of the likelihood surfaces for the frequentist models (Figure 3)
show more regular elliptical surfaces for the GLM model which suggests
that asymptotic inference would be more reliable for the GLM. Although
we should be wary of generalizing these results, there seems to be little dif-
ference between the two models in terms of ﬁt, with some possible advantages
to the GLM model.
[Figure 3 about here.]
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In ﬁtting the frequentist models, one individual produced invalid param-
eter estimates under the GLM, with β2 slightly greater than zero. On closer
examination we found that this individual had a diﬀerent proﬁle from the
others, with a much higher initial concentration, and lower time to maximum
concentration, suggesting the model may be inappropriate for this individual.
In the Bayesian analysis the problem of positive β2 was avoided because the
prior excluded such possibilities.
5.2 Population Fitting
We ﬁtted generalized linear and non-linear mixed eﬀects models, with all
parameters random; results are summarized in Table 1. For the Bayesian
models we used independent lognormal priors on the ﬁxed eﬀects, with me-
dian and 90th percentile as in the individual ﬁtting, and an inverse Wishart
prior for Σ−1, which requires speciﬁcation of a scale matrix and a degrees
of freedom. For the former we choose a diagonal matrix with elements 0.04,
which corresponds to 20% coeﬃcient of variation for the parameters on the
non-logarithmic scale (Wakeﬁeld et al. (1994)). Lower degrees of freedom
correspond to ﬂatter distributions and so we chose a value of three, which
is the lowest value that produces a proper posterior. The GLMM ran much
faster than the non-linear MEM; 0.66 seconds versus 36.5 seconds. The
Bayesian models are more diﬃcult to compare since the GLMM was imple-
mented in WinBUGS while the compartmental model required speciﬁc R code
to be written (because of the need for root-solving).
[Table 1 about here.]
The frequentist GLMM gives slightly diﬀerent results to the other models,
since the random eﬀects are normal on the β scale, rather than log-normal.
13
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As before, there is little diﬀerence between estimates from the GLM and com-
partment models. With only 12 individuals we might question the sensitivity
to the scale matrix in the Wishart distribution. For this example, however,
inference was relatively insensitive to this choice. When we chose diagonal
elements 0.01 and 0.25 (corresponding to approximate coeﬃcients of varia-
tion of 10% and 50%, respectively); the medians were largely unchanged and
the interval estimates moved in the expected directions. For example, for
the GLMM the biggest changes were for t1/2 and cmax. For t1/2 the interval
estimates were (7.04,8.33), (6.99,8.42), (6.83,8.71) under diagonal elements
0.01, 0.04, 0.25, and for cmax the corresponding estimates were (8.08,9.64),
(8.05,9.70), (7.83,9.92).
6. Discussion
We have presented an alternative formulation to compartment models for
pharmacokinetic data with single doses. If multiple doses are considered
the mean function does not correspond to a GLM and so the models lose a
lot of their appeal. We would also not advocate the use of the GLM mean
function for predicting pharmacokinetic behavior under multiple doses, since
the steady-state behavior has not been investigated.
An advantage of the GLM is that it is generally easier to ﬁt. For single
individuals it takes the form of a standard GLM, and likelihood surfaces
are more regular. From a computational point of view the Bayesian models
beneﬁt from the straightforward conversion between the β model parameters
and θ the derived parameters of interest; the compartment model needs to
use numerical root-solving for this conversion.
A disadvantage of the GLM model is that it is only interpretable for
14
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β1 < 0, β2 < 0, and it is possible to obtain estimates that do not correspond
to real-valued estimates of the parameters of interest. When we observed this
in our data it seemed to indicate that the model was inappropriate, suggesting
model reﬁnement was required. The problem of uninterpretable estimates
may be overcome in the Bayesian approach by placing priors directly on the
parameters of interest, since this imposes the constraints as illegal values
have no support under the prior. We can reparameterize for the frequentist
approach, but the model is no longer a GLM though retains the advantage
of being able to easily convert between parameterizations without requiring
root-solving.
This paper has concentrated on the GLM as an alternative to the one-
compartment model with ﬁrst-order absorption. However, the approach may
easily be extended to mimic the behavior of multiple compartment models by
inclusion of extra terms, for example t−2 and/or t−1/2. We might for example
consider a model of the form
µ(t) = D exp
(
β0 + β1t + β2/t + β3/t
2
)
. (10)
The aim is to provide a simple class of model that mimic the qualitative
behavior of compartmental models. For any given GLM formulation we
can calculate the parameters of interest, though this may require numerical
methods. We should take care to ensure that the area under the curve is
ﬁnite for any prospective model, to ensure ﬁnite clearance. For example, the
canonical reciprocal link does not provide a ﬁnite area when combined with
mean function (3).
For compartment models it is common to model volume of distribution
as a function of covariates, such as weight. The term exp(β0) is related to
15
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the volume, suggesting that covariates could be included in β0 for the GLM
formulation. Thus an obvious extension is to incorporate covariates Z in the
natural way, by multiplying the mean concentration by exp(γTZ).
Appendix
We give the variances for the logs of estimators of parameters of interest in
the one-compartment model:
var(log ĉv) ≈
φ2var(φ−1)
4
var(log t̂1/2) ≈
var(β1)
β21
var(log t̂max) ≈
var(β1)
4β21
+
var(β2)
4β22
−
cov(β1, β2)
4β1β2
var(log ĉmax) ≈ var(β0) +
(
β2
β1
)
var(β1) +
(
β1
β2
)
var(β2) + 2cov(β1, β2)
−2
(
β2
β1
)
1/2
cov(β0, β1)− 2
(
β1
β2
)
1/2
cov(β0, β2)
The variance for clearance is more complex but can be calculated as
D1 =
1
β1
−
(
β2
β1
)
1/2
K0[2(β1β2)
1/2]
K1[2(β1β2)1/2]
D2 = −
(
β1
β2
)
1/2
K0[2(β1β2)
1/2]
K1[2(β1β2)1/2]
var(log Ĉl) = var(β0) + D
2
1var(β1) + D
2
2var(β2)− 2D1cov(β0, β1)
−2D2cov(β0β2) + 2D1D2cov(β1, β2)
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Figure 1. Concentrations of Theophylline versus time for 12 individuals,
along with ﬁtted curves; the solid lines correspond to the GLM and the
dashed lines to the compartmental model.
19
Hosted by The Berkeley Electronic Press
t1
2
Density
8
10
12
14
16
18
20
0.00 0.05 0.10 0.15 0.20
Com
partm
ent
tm
a
x
Density
1.5
2.0
2.5
3.0
0.0 0.5 1.0 1.5 2.0
Clearance
Density
0.016
0.018
0.020
0.022
0.024
0 50 100 150 200
t1
2
Density
8
10
12
14
16
18
20
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35
G
LM
tm
a
x
Density
1.5
2.0
2.5
3.0
0.0 0.5 1.0 1.5 2.0 2.5
Clearance
Density
0.016
0.018
0.020
0.022
0.024
0 50 100 150 200 250 300
Figure2.Histogramsofposteriorsamplesfort
1/2
,t
max
andclearancefor
theﬁrstindividualunderthecompartmentmodel(toprow)andtheGLM
(bottomrow).
20
http://biostats.bepress.com/uwbiostat/paper309
−
3
−
2
−
1
0
1
−1.0−0.50.00.51.01.5
Co
m
pa
rtm
en
t
lo
g(V
)
log(k
a
)
−
3
−
2
−
1
0
1
−6−4−20
Co
m
pa
rtm
en
t
lo
g(V
)
log(k
e
)
−
1.
0
−
0.
5
0.
0
0.
5
1.
0
1.
5
−6−4−20
Co
m
pa
rtm
en
t
lo
g(k
a
)
log(k
e
)
0
1
2
3
−0.20−0.15−0.10−0.050.000.050.10
G
LM β 0
β
1
0
1
2
3
−1.0−0.50.00.5
G
LM β 0
β
2
−
0.
20
−
0.
15
−
0.
10
−
0.
05
0.
00
0.
05
0.
10
−1.0−0.50.00.5
G
LM β 1
β
2
Figure 3. Likelihood surfaces for the ﬁrst individual for the compartment
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Table 1
Comparison of ﬁxed eﬀects for mixed eﬀects analyses: parameter estimates
(for the Bayesian analyses posterior medians are given) and 95% interval
estimates. Estimates for the maximum concentration are for a dose of 5mg.
Compartment GLM
Parameter Fixed eﬀect (95% interval) Fixed eﬀect (95% interval)
FREQUENTIST
t1/2 7.75 ( 7.06, 8.51 ) 7.58 ( 6.88, 8.35 )
tmax 2.26 ( 1.73, 2.96 ) 2.17 ( 1.89, 2.49 )
cmax 9.06 ( 8.15, 10.1 ) 8.67 ( 7.74, 9.71 )
Cl× 103 40.3 ( 35.0, 46.4 ) 40.5 ( 35.0, 46.9 )
cv × 102 17.1 ( 15.1, 19.5 ) 10.8 ( 9.5, 12.2 )
BAYESIAN
t1/2 7.78 ( 6.80, 8.72 ) 7.66 ( 6.99, 8.42 )
tmax 2.21 ( 1.65, 2.85 ) 2.01 ( 1.68, 2.38 )
cmax 8.73 ( 7.72, 10.0 ) 8.82 ( 8.05, 9.70 )
Cl× 103 41.9 ( 32.4, 54.6 ) 39.8 ( 38.7, 40.8 )
cv × 102 17.2 ( 15.3, 19.8 ) 12.9 ( 11.4, 14.8 )
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